The group's principle activity is to develop novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). The group's technology includes CNSProfile(TM) technology. The group's core therapeutic programs include Schizophrenia, Sleep Disorders, Parkinson's and Alzheimer's Disease, Chemical Defense, and Womens Health Program. The group operates from United States.
